
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4127834/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2022, 28, 48.e1-48.e10.	1.2	18
2	Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics. Blood Reviews, 2022, 53, 100906.	5.7	17
3	Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 2022, 185, 881-895.e20.	28.9	605
4	Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients. Clinical Microbiology and Infection, 2022, 28, 1345-1350.	6.0	2
5	Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 304.e1-304.e9.	1.2	12
6	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Review of Hematology, 2022, 15, 305-320.	2.2	25
7	Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center. Transplantation and Cellular Therapy, 2022, 28, 511.e1-511.e10.	1.2	5
8	Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 619.e1-619.e8.	1.2	7
9	Liquid Biopsy for Invasive Mold Infections in Hematopoietic Cell Transplant Recipients With Pneumonia Through Next-Generation Sequencing of Microbial Cell-Free DNA in Plasma. Clinical Infectious Diseases, 2021, 73, e3876-e3883.	5.8	51
10	Donor-Derived CD4+ T Cells and Human Herpesvirus 6B Detection After Allogeneic Hematopoietic Cell Transplantation. Journal of Infectious Diseases, 2021, 223, 709-713.	4.0	4
11	Tocilizumab in hospitalized patients with COVIDâ€19: Clinical outcomes, inflammatory marker kinetics, and safety. Journal of Medical Virology, 2021, 93, 2270-2280.	5.0	32
12	Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer. Cancer Investigation, 2021, 39, 205-213.	1.3	17
13	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight, 2021, 6, .	5.0	18
14	A eulogy for Dr Francisco Miguel Marty Forero. Transplant Infectious Disease, 2021, 23, e13645.	1.7	0
15	Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. Blood Advances, 2021, 5, 3113-3119.	5.2	24
16	Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection. Transplantation and Cellular Therapy, 2021, 27, 684.e1-684.e9.	1.2	2
17	Humoral Immunity After mRNA SARS-CoV-2 Vaccination in Allogeneic HCT Recipients—Room for Improvement and Much to Learn. JAMA Network Open, 2021, 4, e2127454.	5.9	8
18	Association of Inherited Chromosomally Integrated Human Herpesvirus 6 with Neurologic Symptoms and Management after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 795.e1-795.e8.	1.2	4

#	Article	IF	CITATIONS
19	Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	27.6	37
20	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. , 2021, 9, e003428.		11
21	Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 413-420.	2.0	40
22	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biology of Blood and Marrow Transplantation, 2020, 26, 26-33.	2.0	222
23	Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6. Biology of Blood and Marrow Transplantation, 2020, 26, 254-261.	2.0	7
24	Unbiased optical mapping of telomere-integrated endogenous human herpesvirus 6. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31410-31416.	7.1	18
25	To Toci or Not to Toci for Coronavirus Disease 2019 (COVID-19): Is That Still the Question?. Clinical Infectious Diseases, 2020, 73, e455-e457.	5.8	1
26	Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. Current Opinion in Infectious Diseases, 2020, 33, 449-457.	3.1	21
27	Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open Forum Infectious Diseases, 2020, 7, ofaa121.	0.9	85
28	How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood, 2020, 136, 925-935.	1.4	158
29	Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. Blood Advances, 2020, 4, 1232-1241.	5.2	16
30	CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Reviews, 2019, 38, 100596.	5.7	109
31	Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e321-e330.	2.0	26
32	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	1.7	22
33	Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation. Blood, 2019, 134, 503-514.	1.4	9
34	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2205	2.0	132
35	2305-2321. Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2019, 37, 2670-2681.	1.6	20
36	In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review. Antiviral Research, 2019, 163, 50-58.	4.1	64

#	Article	IF	CITATIONS
37	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. Bone Marrow Transplantation, 2019, 54, 1354-1360.	2.4	19
38	Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infectious Diseases, The, 2019, 19, e260-e272.	9.1	285
39	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
40	Herpesviruses: Silent Instigators of Lung Injury after Hematopoietic Cell Transplant. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 8-10.	5.6	5
41	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Advances, 2019, 3, 3590-3601.	5.2	52
42	Human herpesvirus 6 in transplant recipients: an update on diagnostic and treatment strategies. Current Opinion in Infectious Diseases, 2019, 32, 584-590.	3.1	29
43	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019. 25. e76-e85.	2.0	85
44	RNA Sequencing of the <i>In Vivo</i> Human Herpesvirus 6B Transcriptome To Identify Targets for Clinical Assays Distinguishing between Latent and Active Infections. Journal of Virology, 2019, 93, .	3.4	16
45	Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. Haematologica, 2019, 104, 2155-2163.	3.5	82
46	Multiple transmissions of chromosomally integrated human herpesvirusâ€6 in one family. Transplant Infectious Disease, 2018, 20, e12816.	1.7	3
47	Alveolar levels of immuno-inflammatory mediators in diffuse alveolar hemorrhage after allogeneic transplant. Bone Marrow Transplantation, 2018, 53, 1206-1209.	2.4	3
48	Reply to Giménez et al. Clinical Infectious Diseases, 2018, 67, 807-808.	5.8	1
49	Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation. Clinical Infectious Diseases, 2018, 66, 368-375.	5.8	56
50	Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy. Blood, 2018, 131, 121-130.	1.4	374
51	Advances in the Characterization of the T-Cell Response to Human Herpesvirus-6. Frontiers in Immunology, 2018, 9, 1454.	4.8	12
52	Reply to Author. Biology of Blood and Marrow Transplantation, 2018, 24, 2166.	2.0	0
53	Comparative genomic, transcriptomic, and proteomic reannotation of human herpesvirus 6. BMC Genomics, 2018, 19, 204.	2.8	45
54	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood, 2017, 129, 2316-2325.	1.4	126

#	Article	IF	CITATIONS
55	Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6. Blood, 2017, 130, 1062-1069.	1.4	65
56	Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies. Biology of Blood and Marrow Transplantation, 2017, 23, 505-511.	2.0	35
57	Kinetic Features of Double Stranded DNA Virus Detection after Allogeneic Hematopoietic Cell Transplantation. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
58	Detection of Human Herpesvirus 6B (HHV-6B) Reactivation in Hematopoietic Cell Transplant Recipients with Inherited Chromosomally Integrated HHV-6A by Droplet Digital PCR. Journal of Clinical Microbiology, 2016, 54, 1223-1227.	3.9	39
59	Efficient identification of inherited chromosomally integrated human herpesvirus 6 using specimen pooling. Journal of Clinical Virology, 2016, 77, 71-76.	3.1	20
60	Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically III Adults*. Critical Care Medicine, 2015, 43, 1415-1422.	0.9	39
61	Prevalence of Chromosomally Integrated Human Herpesvirus 6 in Patients with Human Herpesvirus 6–Central Nervous System Dysfunction. Biology of Blood and Marrow Transplantation, 2015, 21, 371-373.	2.0	22
62	Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation Is Frequent and Persistent. Blood, 2015, 126, 3104-3104.	1.4	1
63	1225Co-Reactivation of Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) is Associated with Worse Clinical Outcome in Critically III Immunocompetent Adults. Open Forum Infectious Diseases, 2014, 1, S43-S43.	0.9	Ο
64	Prevalence of Chromosomally Integrated Human Herpesvirus 6 (HHV-6) Among Patients with HHV-6-Associated Post-Stem Cell Transplant Acute Limbic Encephalitis. Biology of Blood and Marrow Transplantation, 2014, 20, S229-S230.	2.0	0
65	Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation. Journal of Clinical Virology, 2014, 61, 289-292.	3.1	34
66	Intracranial Mycotic Aneurysm Associated With Left Ventricular Assist Device Infection. Annals of Thoracic Surgery, 2014, 98, 1088-1089.	1.3	16
67	Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials. Current Opinion in Virology, 2014, 9, 53-60.	5.4	42
68	Past, present, and future perspectives on the diagnosis of Roseolovirus infections. Current Opinion in Virology, 2014, 9, 84-90.	5.4	18
69	Human herpesvirus 6 and the nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 123, 327-355.	1.8	13
70	Hepatitis Due to Human Herpesvirus 6 after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S228-S229.	2.0	3
71	Cord-Blood Hematopoietic Stem Cell TransplantÂConfers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: AÂCohort Analysis. Biology of Blood and Marrow Transplantation, 2012, 18, 1638-1648.	2.0	141
72	HHV-6-Associated Post-Transplantation Acute Limbic Encephalitis Following Cord Blood Stem Cell Transplantation: A Cohort Analysis. Blood, 2011, 118, 649-649.	1.4	0

#	Article	IF	CITATIONS
73	Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance. Journal of Experimental Medicine, 1998, 187, 2037-2044.	8.5	328